Pinealon

Pinealon

Pinealon is a short Russian-developed peptide, just three amino acids (Glu-Asp-Arg, sometimes called EDR), that's been studied mainly as a brain-protective and cognitive support agent. Most people take it in short cycles when they want to defend the brain against the kind of damage that piles up from age, poor sleep, hangovers, hypoxia, chronic stress, or recovering from a head injury or stroke.
Unlike most peptides, it has documented oral bioavailability, which means you don't have to inject it. It doesn't work like a stimulant. You won't feel it kick in the way you would with caffeine or modafinil. The effect, if you notice anything subjective at all, is more like things hold up better under load. Memory feels less foggy after a bad night's sleep, headaches resolve faster, you bounce back from cognitive strain quicker. The strongest practical case for it is in people who already have measurable cognitive decline (post-concussion, post-stroke, age-related memory issues), or who are trying to protect against future decline.
Almost all the research comes from one Russian lab (Khavinson's group at the St. Petersburg Institute of Bioregulation), and there's very little independent replication in the West. The mechanism is plausible, the safety record is good, but the evidence base is thin.

Deep-dive

Pinealon belongs to a family of "short peptide bioregulators" developed by Vladimir Khavinson over the last 40 years. The original idea was that the body uses very short peptides (2-4 amino acids) as epigenetic signals, telling cells which genes to turn on and off. EDR was identified as a fragment originally found in Cortexin, a polypeptide brain extract used in Russia for stroke and dementia treatment.
The proposed mechanism is unusual. Most peptides bind to a receptor on the cell surface. Khavinson's group has argued, with molecular modeling and DNA docking studies, that EDR is small enough to cross the cell membrane and bind directly to specific DNA sequences in the promoter regions of genes, modulating their expression. The genes EDR has predicted binding sites in include CASP3 (apoptosis), SOD2 (antioxidant), GAP43 (neuroplasticity), APOE (Alzheimer's risk), NES (nestin, neural stem cells), and PPARA/PPARG (metabolism and inflammation). Whether this DNA-binding mechanism is the actual primary mode of action or whether other pathways are involved is still debated. The molecular modeling is suggestive, not proven.
Antioxidant and neuroprotection in vitro. The clearest in vitro finding is that pinealon suppresses reactive oxygen species in cerebellar granule cells, neutrophils, and PC12 (pheochromocytoma) cells under oxidative stress, and reduces necrotic cell death. The protection comes with a delayed activation of ERK 1/2 signalling and changes to the cell cycle, which is what makes the authors suspect EDR is doing more than just scavenging free radicals, it's directly modulating the cell's stress response programming.
Antihypoxic effects. Among a panel of short peptides tested in a hypobaric hypoxia model (low oxygen pressure), pinealon had the strongest neuroprotective effect. The mechanism appears to combine upregulation of endogenous antioxidant enzymes with limiting NMDA-mediated excitotoxicity, the kind of neuronal damage that happens in stroke, traumatic brain injury, and severe alcohol withdrawal.
Alzheimer's mouse model. In a 2021 study in 5xFAD mice (the standard genetic mouse model of Alzheimer's), daily EDR injections prevented the characteristic loss of dendritic spines in the hippocampus. Dendritic spines are the structural connection points between neurons, and their loss correlates closely with cognitive decline in human Alzheimer's. EDR also restored spine numbers in amyloid-stressed hippocampal cultures and in mouse models of Huntington's disease, suggesting the protective effect isn't disease-specific but a general restoration of synaptic resilience under stress.
Prenatal stress protection. In a maternal hyperhomocysteinemia model, pregnant rats with chronically elevated homocysteine (an inflammatory marker linked to neurodevelopmental damage in the offspring) were given pinealon. Their pups showed significantly improved cognitive function and cerebellar neurons that were measurably more resistant to oxidative stress compared to untreated offspring. This isn't a recommendation to take pinealon during pregnancy, the human safety data is far too limited, but it does point to the peptide's strong activity in protecting developing nervous tissue against inflammatory stress.
Human data on cognitive recovery. The strongest piece of human evidence is a clinical trial described in a 2021 review, 72 patients aged 30-74 with cerebrasthenia (the lingering cognitive impairment, headaches, and emotional lability that can follow traumatic brain injury) were given oral pinealon at 0.2 mg twice daily for 20-30 days alongside their standard rehab. Compared to 37 controls on standard therapy alone, the pinealon group reported better memory, lower headache intensity and duration, more stable mood, and better work performance. On a proof-correction test (a measure of sustained attention and information processing), error rates dropped and EEG alpha-index rose, consistent with improved neuroplasticity. This is a single-centre Russian trial, not blinded by Western standards, but the effect size was notable and it's the practical basis for the oral dosing protocol most people use.
Women. Most of the rodent and cell-culture work has been done in mixed or unspecified populations and the existing human trial included both sexes without reporting sex-stratified results. There's no evidence pinealon works differently in women, but there's also no specific data on dose response, hormonal interactions, or menopause-related cognitive symptoms. Two angles are worth flagging anyway. First, women have a roughly two-fold higher lifetime risk of Alzheimer's disease compared to men, and accelerated transcriptomic changes in the female prefrontal cortex with age overlap with the gene-expression patterns EDR is proposed to influence, so the rationale for use in midlife and beyond is at least as strong in women as in men. Second, the maternal homocysteine study is the only one specifically in female animals, and it showed neuroprotection of the offspring rather than the mother, so it tells us almost nothing about how the compound behaves in adult women themselves. Skip it in pregnancy and breastfeeding regardless. For postmenopausal women dealing with cognitive fog, on paper this should work as well as or better than in men, but the evidence to back that up isn't there yet.
Limitations of the evidence. Almost everything published comes from Khavinson's group or affiliated Russian institutions. The DNA-binding mechanism is theoretically interesting but hasn't been independently confirmed in Western labs. Most studies are small, in rodents, or in cell culture. Human trials are limited, unblinded, and concentrated in specific patient populations (post-TBI, elderly with cognitive decline). There are no Western-standard randomised controlled trials in healthy adults. The peptide also overlaps mechanistically with the Khavinson family more broadly (Epitalon, KED, vilon, vesugen), and these compounds are often discussed interchangeably in the literature, which can muddy interpretation. Take the strong-sounding claims about "4,000 genes regulated" or telomere effects with appropriate skepticism, these come from the same source and haven't been validated outside it.

Dosage:

  • Oral (capsules): 0.2 mg twice daily for 20-30 days. This is the dose used in the human TBI trial and is the most common protocol for cognitive recovery and neuroprotection. Take with water, ideally away from large protein meals
  • Subcutaneous injection: 100-300 mcg daily for 10-20 days. Slightly more bioavailable than oral but the practical difference for a short tripeptide is modest, oral is fine for most people
  • Sublingual drops: if using a liquid formulation, 5-6 drops held under the tongue for 30-60 seconds, 2-4 times daily. Bypasses first-pass metabolism, sits between oral and injection in bioavailability
  • Cycling: the protocol is short courses, not continuous use. 2-4 weeks on, then off for at least a month. The proposed mechanism (gene expression changes that persist after the peptide clears) is consistent with intermittent dosing, daily indefinite use isn't necessary and isn't supported by any of the trials
  • Timing: morning dosing is typical when the goal is cognitive support. If you're using it for sleep or circadian regulation, evening makes more sense, though pinealon is not primarily a sleep peptide despite the name
  • Stacks: pairs reasonably with Semax (different mechanism, BDNF/MAPK activation) for cognitive performance, and with Cerebrolysin for post-stroke or post-TBI recovery (overlapping but more aggressive neurotrophic support). Less rationale for stacking with stimulants, pinealon is doing structural maintenance, not acute performance
  • Women specifically: no dose adjustment is needed, but skip during pregnancy and breastfeeding regardless of theoretical benefits to offspring (the human safety data isn't there). Postmenopausal women considering it for cognitive symptoms can use the same 0.2 mg twice daily protocol

Here's what you can expect:

Not much in the first week. Pinealon doesn't produce an acute subjective effect the way stimulants or anxiolytics do. The point isn't to feel different right now, it's to support how the brain copes with stress and ages over time.
During a 3-4 week course, most users report subtle changes by week 2-3: clearer thinking after poor sleep, less mental fatigue at the end of long workdays, faster recovery from headaches or hangovers, slightly better short-term memory for names, conversations, what you went into a room for. The people who notice the most are those starting from a place of cognitive impairment, post-concussion, recovering from significant stress or sleep deprivation, or with age-related decline. If you're a well-rested 28-year-old with no symptoms, you'll probably notice nothing.
The benefit, if real, is supposed to persist for weeks to months after the course ends, since the proposed mechanism is gene expression change rather than ongoing receptor activation. This is also why repeated short courses (2-3 per year) are the standard approach rather than daily use.

Side effects & risks:

  • Generally well tolerated in the limited human trials available. The 72-patient TBI trial reported no significant adverse events beyond what was seen in the control group
  • Mild headache, dizziness, or fatigue during the first few days have been reported anecdotally, usually resolving as the course continues
  • Injection site reactions if using subcutaneous administration, redness, mild swelling, transient discomfort. Rotate sites
  • No established interactions with medications, but the evidence base is too thin to be confident. If you're on antiepileptics, antidepressants, or neurological medications, talk to a doctor before adding it
  • Active cancer: caution. The same gene expression and antiapoptotic signalling that protects healthy neurons could theoretically support tumour cell survival. Avoid during active malignancy or recent diagnosis
  • Pregnancy and breastfeeding: skip it. The prenatal hyperhomocysteinemia data is interesting but doesn't translate to a safety endorsement, there's no human safety data in pregnancy
  • Children and adolescents: not enough data. The peptide has been used in elderly cohorts, not in development
  • Source quality matters more than usual. Pinealon is sold as a research chemical, not a regulated pharmaceutical, and purity varies widely between suppliers. Bad batches can contain contaminants, endotoxins, or simply not contain what the label says. If you're going to use it, source from a vendor that publishes third-party HPLC and mass spec results for each batch
  • Long-term safety data is essentially nonexistent. The longest human trial ran 30 days. Anyone using it for years across multiple cycles is in unexplored territory
Sold as a research chemical or laboratory peptide in most jurisdictions, not approved as a pharmaceutical outside Russia.